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ABSTRACT
Introduction: Only limited information is
available on cost efficacy of the various
biological agents used to treat patients with
rheumatoid arthritis with intolerance or for
whom it would be inappropriate to continue
treatment with conventional agents. We
estimated the efficacy and treatment costs of
monotherapy with biological agents in the
treatment of this group of patients.
Methods: Data from two previous
meta-analyses in the treatment of patients
who are intolerant to methotrexate (MTX), or
for whom it would be inappropriate to continue
treatment with MTX was used.
Pharmacoeconomic comparison between
biological agents was carried out to estimate
the respective cost for the number needed to
treat (NNT) compared to placebo using both
American College of Rheumatology (ACR) and
European League Against Rheumatism (EULAR)
criteria. The analysis involved the four agents
approved in Italy: adalimumab (ADA),
etanercept (ETN), certolizumab pegol (CTZ),
and tocilizumab (TCZ). A six-month period
was considered sufficient to understand the
most important differences in efficacy and
treatment costs. Direct medical costs,
including pharmacological therapy,
administration and monitoring were
considered.
Results: Using both ACR and EULAR criteria,
TCZ (intravenous [iv]/subcutaneous [sc]) had a
lower NNT than the other agents. The
difference in NNT observed for ETN was more
pronounced with EULAR criteria, whereas in
the comparison with ADA, the most sensitive
differences were observed with ACR criteria.
ETN had the lowest treatment cost (€6402.19),
followed by ADA (€6698.84), TCZ sc (€6887.61),
and TCZ iv (€7130.83). TCZ sc had the lowest
cost for NNT with both ACR and EULAR criteria.
The differences compared to ETN and ADA were
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significant and related with the level of efficacy.
Sensitivity analysis confirmed these results.
Conclusion: TCZ is a cost-effective therapeutic
option compared to other tumor necrosis
factor-a inhibitors (ADA, ETA, CTZ) as first-line
monotherapy for patients who are intolerant to
MTX, or for whom it is inappropriate to
continue treatment with MTX.
Funding: Roche SpA.
Keywords: Adalimumab; Biological agents;
Certolizumab; Etanercept; Number needed to
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arthritis; Rheumatology; Tocilizumab
INTRODUCTION
Rheumatoid arthritis (RA) is a systemic
autoimmune disease characterized by chronic
inflammation of synovial joints [1, 2]. The
persistence of intra-articular inflammation
causes cartilage destruction and bone erosion,
leading to peripheral joint deformation and
disability. Joint damage and functional loss are
present at the very early stages, but the rate of
progression of disease varies among individual
patients [3, 4].
The global prevalence of RA in the adult
population is estimated to be 0.5–1%; however,
it appears to depend greatly on the geographical
area (Japan 0.2%, Netherlands 1–1.5%,
Scandinavian Peninsula 3%, Spain 0.5%, and
United States 1%) [5, 6]. In Italy, two
observational studies estimated a prevalence of
0.33% in Liguria and 0.31% in Lombardy [5, 7].
Despite its relatively low prevalence, RA is
associated with significant disability and high
economic and social impact [8]. Conventional
disease-modifying anti-rheumatic drugs
(cDMARDs), such as methotrexate (MTX),
represent the first-line of treatment, whereas
biologic disease-modifying anti-rheumatic
drugs (bDMARDs) constitute second-line
strategy and are recommended in all patients
with inadequate response or who are intolerant,
or for whom it would be inappropriate to
continue treatment with cDMARDs [9, 10].
The use of bDMARDs has brought significant
progress in RA therapy as they allow a very high
proportion of patients to achieve clinical
remission or low disease activity, with a
concomitant reduction of long-term disability
[11–15]. In most cases, bDMARDs—including
adalimumab (ADA), abatacept, infliximab,
etanercept (ETN), certolizumab (CTZ),
golimumab, rituximab, and tocilizumab
(TCZ)—are administered in combination with
MTX for the treatment of moderate to severe RA
in adult patients with an inadequate response to
MTX. In other cases, some of these agents (ADA,
ETN, CTZ, and TCZ) can be used as
monotherapy in the treatment of RA patients
who are intolerant to MTX, or for whom it is
inappropriate to continue treatment with MTX.
By focusing attention on this latter therapeutic
indication, the aimof this analysis was to estimate
the efficacy and treatment costs of monotherapy
with bDMARDs in treatment of RA patients who
are intolerant to MTX, or for whom it is
inappropriate to continue MTX treatment.
METHODS
Clinical Data
The main criteria for evaluating improvement
or clinical response to pharmacological
treatment for RA are those recommended by
the American College of Rheumatology (ACR)
and the European League Against Rheumatism
(EULAR). Both these societies have reached
consensus regarding the minimum number of
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active disease variables (core set) to be measured
to evaluate the efficacy of treatment [16]. These
variables include: number of painful and
swollen joints, measurement of residual
functional abilities, serological evaluation of
acute phase reactants (erythrocyte
sedimentation rate [ESR] and C-reactive
protein [CRP]), and opinion of disease activity
expressed by both the doctor and patient, in
addition to that on the intensity of pain
perceived by the patient [17]. EULAR criteria
are based on absolute values and on changes in
the disease activity score (DAS)/DAS28
compared to baseline (assessment and classify
response to treatment as good, moderate, or
absent) [18]. ACR criteria evaluate the
improvement (20%, 50%, 70%) in all core set
variables [16]. Despite being different, both
criteria are used routinely in clinical trials.
The present economic analysis is based on
two meta-analyses that focused on the efficacy
of bDMARD monotherapy for the treatment of
RA [19, 20]. The first, carried out by Orme et al.
[20] using the main medical databases (Medline,
Embase, and Cochrane Library), considered all
randomized phase 2 and 3 clinical studies on
the treatment of patients with RA using ACR
(ACR 20, 50, and 70) criteria as the clinical
endpoint. In line with the main objective of the
present analysis, Table 1 shows the details of the
estimated efficacy data (vs. placebo) for the
bDMARDs used in monotherapy.
The second meta-analysis, which is a ‘‘final
appraisal determination’’ from the UK National
Institute for Health and Care Excellence (NICE)
[19], available online, evaluated the efficacy of
bDMARDs in the treatment of treatment-naive
patients with RA or those who failed previous
treatment with cDMARDs using EULAR criteria.
The efficacy results (vs. placebo) are shown in
Table 2 and refer to biologics used as
monotherapy [19].
Table 1 ACR 20, 50, and 70: bDMARDs monotherapy vs. placebo [20]
Treatments ACR 20 ACR 50 ACR 70
Placebo 14.1% (11.1%, 17.7%) 5.9% (3.9%, 8.7%) 1.3% (0.6%, 3.1%)
ADA 40 mg/EOW 44.8% (32.4%, 57.9%) 23.2% (12.5%, 39.8%) 13.2% (3.6%, 42.8%)
ETN 2 9 25 mg/week 66% (45.6%, 83.4%) 46.4% (21.3%, 78.1%) 20.9% (3.3%, 92%)
TCZ 8 mg/kg/4 weeks 81.1% (61%, 92.8%) 74.7% (31.2%, 98.3%) 43% (5.4%, 98.9%)
ACR American College of Rheumatology, ADA adalimumab, bDMARDs biologic disease-modifying anti-rheumatic drugs,
EOW every other week, ETN etanercept, TCZ tocilizumab
Table 2 EULAR criteria: bDMARD monotherapy vs. placebo [19]
Treatments Moderate response Good response
Placebo 50% (7%, 94%) 12% (5%, 65%)
ADA 40 mg/EOW 76% (33%, 98%) 31% (5%, 78%)
ETN 2 9 25 mg/week 71% (12%, 99%) 26% (1%, 87%)
TCZ 8 mg/kg/4 weeks 93% (77%, 99%) 61% (32%, 88%)
ADA adalimumab, bDMARDs biologic disease-modifying anti-rheumatic drugs, EOW every other week, ETN etanercept,
EULAR European League Against Rheumatism, TCZ tocilizumab
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Both meta-analyses are identified TCZ as the
most efficacious monotherapy in the treatment
of patients who are intolerant to MTX, or for
whom it would be inappropriate to continue
treatment with MTX [19, 20].
Number Needed to Treat
Methodological progresses have led to the
development of instruments specific to the
field of pharmacoeconomic evaluation, with
the final aim to calculate the incremental
cost-effectiveness ratio (ICER). This indicator
allows decision-makers to know at what
additional cost it is possible to purchase an
additional unit of result, expressed in the form
of quality-adjusted life years (QALY). Once the
ICER per QALY has been calculated, to verify its
acceptability, it must be compared with a
reference ‘‘threshold value’’, which according
to AIES (Associazione Italiana di Economia
Sanitaria) guidelines, should be €40,000 [21]. It
is important to remember that the purpose of
this threshold which is calculated considering
quality-adjusted or unadjusted survival as its
outcome is to express the decision-maker’s
willingness to pay to obtain an additional unit
of health (QALY).
In this specific case, the two meta-analyses
considered [19, 20] did not provide, among the
various outcomes evaluated, any results in
terms of simple life years (LY) or QALY. Thus,
an incremental analysis approach can be
applied, since it would not have been possible
to calculate an ICER per life year gained to be
compared with the reference threshold value;
however, it would have been possible to
determine an ICER for an ‘intermediate’
outcome (e.g., ICER per patient at the
therapeutic target), but that cannot be
compared with the reference threshold value
[21].
To overcome the problem of finding a result
indicator without being able to evaluate its
quality, it was decided to perform a
pharmacoeconomic comparison between
bDMARDs with the aim of estimating the
respective cost for the number needed to treat
(NNT) compared to placebo [22, 23]. This
indicator represents the number of patients to
be treated to obtain a given therapeutic benefit,
or in this case the number of patients that has to
be treated with a specific bDMARD compared to
placebo to obtain a responder, in which efficacy
is measured using both ACR and EULAR criteria.
Hence, by multiplying this indicator by the
relative cost of treatment, the cost of NNT
associated with the bDMARDs can be
calculated.
Time Horizon and Perspective
When comparing two or more healthcare
technologies for pharmacoeconomic purposes,
national [21] and international guidelines
[25, 26] recommend the use of a time horizon
suited to understand all the main differences
expressed in terms of both outcomes and
treatment costs. Given that in the majority of
the clinical studies considered in the two
meta-analyses, the median follow-up efficacy
period was 24 weeks; it was decided that for this
analysis, a 6-month period would be adequate
to understand the most important differences
in efficacy and treatment costs.
The economic analysis was conducted from a
National Health Service (NHS) perspective.
bDMARDs
As mentioned above, the aim of this analysis
was to explore the efficacy and treatment costs
of bDMARDs with an authorized indication as
monotherapy for patients who are intolerant to
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MTX, or for whom it is inappropriate to
continue treatment with MTX. In Italy, there
are currently four bDMARDs with this
indication: ADA, ETN, CTZ, and TCZ. The first
three, administered via a subcutaneous (sc)
route, are tumor necrosis factor (TNF)-a
inhibitors, while the fourth, administered via
both the sc and intravenous (iv) routes, is an
inhibitor of the interleukin-6 (IL-6) receptor
[19].
The two meta-analyses only provided
efficacy data for three of the four bDMARDs:
ADA, ETA, and TCZ. For this reason, CTZ was
excluded from the base case analysis and
considered only in the sensitivity analysis (see
relevant paragraph in Sensitivity Analysis
section). On the basis of the results of the
SUMMACTA study, which demonstrated that
TCZ sc (162 mg injection a week) and TCZ iv
(8 mg/kg every 4 weeks) have comparable
efficacy, the two meta-analyses did not
distinguish between the two formulations [24].
Treatment Cost
Direct medical costs, such as pharmacological
therapy (bDMARDs), administration and
monitoring were only considered. Other direct
medical costs (i.e., adverse events) were
excluded since they were assumed similar to
all bDMARDs considered.
Table 3 indicates the mean 6-month cost of
the monotherapies included in the comparison.
The per pack cost of the bDMARDs is the
ex-factory price including the temporary
discounts imposed by national law (AIFA
Resolution of 3 July 2006, Official Gazette N.
156 of 7 July 2006, and subsequent AIFA
Resolution of 9 February 2007, Official Gazette
N. 57 of 9 March 2007 and extensions thereof),
excluding any other discounts agreed with NHS
facilities. These costs were calculated
considering the doses indicated in the
respective Summaries of Product
Characteristics.
In line with the procedures implemented in
Italy, the cost of administration was considered
only for the bDMARDs administered
intravenously, whereas no cost was assumed
for sc drugs. The charge applied for an iv
infusion was considered to be €11.62, as
indicated by the national list of charges for
specialist outpatient healthcare services [27].
The healthcare resource consumption
associated with monitoring activities was
calculated using the data indicated in a recent
national experience comparing TCZ iv with
ADA sc [28]. Table 4 indicates the healthcare
Table 3 Mean 6-month cost of treatment with bDMARD monotherapy
bDMARDs Dose Pack Pack price Monthly cost 6-month cost
Tocilizumab (iv)a Every 4 weeks 8 mg/kg €149.25 €1131.77 €6790.65
Tocilizumab (sc) 1 syr OW 4 syr 162 mg €1044.17 €1131.19 €6787.13
Etanercept (sc) 50 mg OW 4 syr 50 mg €969.49 €1050.29 €6301.71
Adalimumab (sc) 40 mg EOW 2 syr 40 mg €1015.13 €1099.73 €6598.36
Certolizumab (sc) 200 mg EOW 2 syr 200 mg €920.55 €997.26 €5983.58
bDMARDs biologic disease-modifying anti-rheumatic drugs, EOW every other week, iv intravenous, OW once a week,
sc subcutaneous, syr syringe
a Assuming an average patient weight of 70 kg
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resource consumption and mean costs for
monitoring activities, making a distinction
between sc and iv regimens, for the 6-month
observation period. Healthcare services were
calculated using the corresponding NHS
charges [27]. The cost of 6 months of
monitoring associated with an iv bDMARD
was almost three times that estimated for sc
bDMARD (€270.46 vs. €100.48).
Sensitivity Analysis
The sensitivity analysis was carried out with the
aim of evaluating the degree of uncertainty of
the results of the base case [29]. It focused on
the key variables of the analysis, i.e., the efficacy
data obtained from the two meta-analyses,
which made it possible to determine the mean
cost for the NNT for the biologics considered. A
first part of the sensitivity analysis was
conducted by simultaneously varying each
efficacy parameter to observe its effect on the
mean cost per NNT, considering first the lower
and then the upper limit of the respective
variability range.
In a second phase, to obtain data on the use
of CTZ monotherapy, the base case results were
recalculated, replacing the ACR response rates
estimated by Orme et al. [20] with those
obtained in another meta-analysis, whose
objectives also included estimating the efficacy
of monotherapy in patients who are intolerant
to MTX, or for whom it is inappropriate to
continue treatment with MTX [30]. In that
meta-analysis, a specific efficacy value (ACR 20,
50, and 70) was calculated for TCZ and a mean
value was calculated for TNF-a inhibitors
among which CTZ was considered, in addition
to ETA and ADA. For the latter, an overall
6-month cost of €6084.06 was considered. In
line with the methods adopted for the other
biologics, the cost was composed of €100.48 for
monitoring and €5983.58 for purchase of the
biologic (Table 3). For the sc bDMARDs, no cost
was considered for administration.
Sensitivity analysis on monitoring and
administration costs was not performed as
they have a minimal impact on overall costs,
and therefore, even significant changes in the
base values would not have produced any
Table 4 Monitoring: mean 6-month costs [28]
Healthcare services Unit cost bDMARDs IV bDMARDs SC
6-month service 6-month cost 6-month service 6-month cost
Visit €20.66 6 €123.96 2 €41.32
Complete blood count €3.17 6 €19.02 2 €6.34
ESR and CRP €5.82 6 €34.92 2 €11.64
Hepatic function €2.04 6 €12.24 2 €4.08
Urea, electrolytes, and creatinine €9.57 6 €57.42 2 €19.14
Chest X-ray €15.49 1 €15.49 1 €15.49
Cholesterol €2.47 3 €7.41 1 €2.47
Total (6 months) €270.46 €100.48
bDMARDs biologic disease-modifying anti-rheumatic drugs, CRP C-reactive protein, ESR erythrocyte sedimentation rate,
IV intravenous, SC subcutaneous
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differences that would substantially affect the
base case results. For different reasons,
sensitivity analysis for the cost of
pharmacological treatment was not carried
out. In the base case, the purchase cost net of
compulsory legal discounts and gross of any
other discounts granted to hospital facilities was
used. As this latter type of discount is hard to
quantify, it was preferred to not consider
alternative scenarios to the base case, which
undoubtedly would not have reflected the
actual situation.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of




Table 5 shows two separate series of NNT for
TCZ (iv/sc), ADA, and ETA. The first series was
calculated using ACR criteria, while EULAR
criteria were used for the second. In both
cases, TCZ (iv/sc) had a lower NNT (higher
efficacy) than the other agents. The difference
in the values observed for ETN was more
pronounced using EULAR criteria, whereas in
the comparison with ADA, the most sensitive
differences were observed with ACR criteria.
Cost of Treatment
Table 6 shows the mean 6-month cost per
treated patient, which is the sum of the
ex-factory drug price plus the costs of
administration and monitoring (these last two
expense items only have a minimal impact on
the overall cost (range 1.5–4.8%). ETN had the
lowest treatment cost (€6402.19), followed by
ADA (€6698.84), TCZ sc (€6887.61), and TCZ iv
(€7130.83). The differences compared to ETN
vary from a minimum of approximately €300
(vs. ADA) to a maximum of about €700 (vs. TCZ
iv).
Cost for NNT
Figures 1 and 2 show the mean cost per NNT
calculated using ACR or EULAR response
Table 5 NNT
NNT vs. placebo TCZ (iv) TCZ (sc) ETN (sc) ADA (sc)
ACR criteria
ACR 20 1.49 1.49 1.93 3.26
ACR 50 1.45 1.45 2.47 5.78
ACR 70 2.40 2.40 5.10 8.40
EULAR criteria
Moderate response 2.33 2.33 4.76 3.85
Good response 2.04 2.04 7.14 5.26
ACR American College of Rheumatology, ADA adalimumab, ETN etanercept, EULAR European League Against
Rheumatism, iv intravenous, sc subcutaneous, TCZ tocilizumab
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criteria. In terms of the percentage of patients
achieving ACR response (20, 50, or 70), TCZ sc
had the lowest cost for NNT. Despite having
higher administration and monitoring costs, iv
TCZ showed lower mean costs for the NNT than
ETN or ADA. The greater the clinical
improvement according to ACR (20, 50, or 70)
criteria, the greater the cost for the NNT
calculated for TCZ (sc/iv) and the cost
calculated for ETN or ADA. The mean cost for
NNT calculated using EULAR response criteria
showed that TCZ sc was the best treatment
option, followed by TCZ iv. The differences
compared to ETN and ADA were significant and
related with the level of efficacy.
Sensitivity Analysis
Table 7 shows the results of the sensitivity
analysis carried out in the light of changes in
efficacy rates in relation to the limits of the
corresponding variability ranges. In almost all
comparisons, TCZ was associated with the lowest
mean costs for NNT, with the exception of the
case considering the upper limit of the confidence
interval for the EULAR criteria, where ETN
appeared to be the most cost-effective option.
Table 8 shows the results of the sensitivity
analysis using efficacy data of the meta-analysis
conducted by Buckley et al. [29]. In this
comparison, TCZ (sc/iv) had the lowest mean
Table 6 Mean 6-month costs of treatment per patient
Costs TCZ (iv) TCZ (sc) ETN (sc) ADA (sc)
Administration €69.72 €0.00 €0.00 €0.00
Monitoring €270.46 €100.48 €100.48 €100.48
Medicinal product €6790.65 €6787.13 €6301.71 €6598.36
Total €7130.83 €6887.61 €6402.19 €6698.84
ADA adalimumab, ETN etanercept, iv intravenous, sc subcutaneous, TCZ tocilizumab
Fig. 1 Mean cost for the NNT: ACR criteria. ACR American College of Rheumatology, ADA adalimumab, ETN
etanercept, NNT number needed to treat, iv intravenous, sc subcutaneous, TCZ tocilizumab
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cost for NNT. The cost-effectiveness of TCZ was
also confirmed compared to CTZ, which was the
biologic with the lowest treatment costs in the
six-month observation period.
DISCUSSION
The present analysis used the NNT as a
synthetic indicator to assess the clinical
Fig. 2 Mean cost for the NNT: EULAR criteria. ACR
American College of Rheumatology, ADA adalimumab,
ETN etanercept, EULAR European League Against
Rheumatism,NNT number needed to treat, iv intravenous,
sc subcutaneous, TCZ tocilizumab
Table 7 Sensitivity analysis (efﬁcacy data variation) [19, 20]
Criteria for the NNT TCZ (iv) TCZ (sc) ETN (sc) ADA (sc)
ACR criteria
ACR lower limit €14,261.66 €13,775.22 €18,566.35 €31,417.56
ACR 20 upper limit €9484.00 €9160.52 €9731.33 €16,680.11
ACR 50 lower limit €26,098.84 €25,208.65 €36,812.59 €77,907.51
ACR 50 upper limit €7986.53 €7714.12 €9219.15 €21,570.26
ACR 70 lower limit €148,535.19 €143,468.92 €237,137.12 €223,272.34
ACR 70 upper limit €7416.06 €7163.11 €7170.45 €16,881.08
EULAR criteria
Moderate response lower limit €10,197.09 €9849.28 €128,043.80 €25,790.53
Moderate response upper limit €142,616.60 €137,752.20 €128,043.80 €167,471.00
Good response lower limit €23,032.58 €22,246.98 N/A N/A
Good response upper limit €31,019.11 €29,961.10 €29,129.96 €51,514.08
ACR American College of Rheumatology, ADA adalimumab, ETN etanercept, EULAR European League Against
Rheumatism, N/A not applicable, NNT number needed to treat, iv intravenous, sc subcutaneous, TCZ tocilizumab
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benefits and costs associated with the use of
different monotherapies (ADA, ETA, CTZ, and
TCZ) in the treatment of patients who are
intolerant to MTX, or for whom it is no longer
appropriate to continue therapy with MTX. The
NNT was calculated using both ACR response
rates, indicated in the meta-analysis conducted
by Orme et al. [20], and EULAR criteria,
obtained from the meta-analysis conducted by
NICE in its recent appraisal [19]. For each
bDMARD, we calculated the respective
6-month costs for purchase, administration,
and monitoring by the NHS.
TCZ had the lowest mean cost for the NNT
calculated with both response criteria, which
were slightly higher for the iv formulation after
administration and monitoring. The costs
calculated for the other sc bDMARDs were
significantly higher. Hence, it was seen that
the greater the clinical improvement, according
to ACR (20, 50, or 70) or EULAR criteria
(moderate or good response), the greater the
difference in NNT costs in favor of TCZ (sc/iv).
While it is worthwhile to discuss the results
of economic analysis by comparing them with
those already published, to the best of our
knowledge there are no other similar
assessments in this specific patient population.
However, three cost-utility analyses that
estimated the incremental cost per QALY for
TCZ compared to other TNF-a inhibitors are
available. In the first study, carried out in
Greece, TCZ had an incremental cost per
QALY of €28,837 compared to the use of other
TNF-a inhibitors in the treatment of patients
intolerant to MTX or for whom it was not
appropriate to continue treatment with MTX
[31]. The second analysis, carried out in the
United States, compared monotherapy with
TCZ or ADA for the treatment of patients with
RA for whom treatment with MTX was not
appropriate [32]. The authors, on the basis of
Table 8 Sensitivity analysis (Buckley et al. [29])
Placebo TCZ (iv) TCZ (sc) ETN (sc) ADA (sc) CTZ (sc)
Efﬁcacy
ACR 20 17.30% 72.90% 72.90% 58.30% 58.30% 58.30%
ACR 50 6.20% 50.50% 50.50% 30.50% 30.50% 30.50%
ACR 70 1.30% 28.80% 28.80% 15.50% 15.50% 15.50%
NNT (calculated compared to placebo)
ACR 20 N/A 1.8 1.8 2.44 2.44 2.44
ACR 50 N/A 2.26 2.26 4.12 4.12 4.12
ACR 70 N/A 3.64 3.64 7.04 7.04 7.04
Cost for the NNT
ACR 20 N/A €12,835.49 €12,397.70 €15,621.34 €16,345.17 €14,845.11
ACR 50 N/A €16,115.68 €15,566.00 €26,377.02 €27,599.22 €25,066.33
ACR 70 N/A €25,956.22 €25,070.90 €45,071.42 €47,159.83 €42,831.78
ACR American College of Rheumatology, ADA adalimumab, CTZ certolizumab, ETN etanercept, N/A not applicable,
NNT number needed to treat, iv intravenous, sc subcutaneous, TCZ tocilizumab
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the results of the ADACTA direct comparison
clinical study, calculated an incremental cost
per QALY of US $36,944 in favor of TCZ
compared with ADA. The third study [33],
from the UK, evaluated the cost-utility of TCZ
in addition to the current sequence of
treatments envisaged for RA. In that report,
two scenarios were explored: one for patients
for whom MTX is contraindicated and one for
tolerant patients. For each of these scenarios,
three different treatment strategies were
compared: (1) standard of care (consisting a
sequence of the most commonly administered
biologics), (2) TCZ as first-line therapy, and (3)
TCZ as second-line therapy. In patients for
whom MTX is contraindicated, TCZ was found
to be cost-effective as both first- and second-line
therapy, whereas in MTX-tolerant patients the
strategy involving the addition of TCZ (first- or
second-line) was found to be similar to that
determined by the standard of care. All three
analyses concluded that TCZ was a
cost-effective option in patients with RA for
whom biologic monotherapy was indicated,
thus confirming the results of the present
analysis with different methods.
To analyze the limits of our study, as
previously mentioned the two meta-analyses
considered did not allow determination of
clinical outcomes expressed in terms of survival
simple or QALY, essentially changing the choice
of assessment method to the cost for the NNT as
an indicator of cost-effectiveness. For this reason,
we compared the bDMARDs by calculating the
number of subjects needed to be treated to
achieve a specific therapeutic target (ACR/
EULAR). With this indicator, it was possible to
determine an order of preference among the
bDMARDs based on cost-effectiveness.
A further aspect that needs to be discussed is
the efficacy data used to calculate the NNT.
Although the two meta-analyses [19, 20]
evaluated a large number of randomized
clinical studies, the efficacy data are
characterized by a broad range of variability.
Given this uncertainty, sensitivity analysis was
required to evaluate its impact on the final
results. It was also seen that by simultaneously
considering the upper or lower extremities of
the efficacy rate variability range (ACR 20, 50,
70, moderate or good response), the results of
the base case were more or less confirmed.
Additionally, as confirmation of the clinical
data used herein, a subsequent analysis
conducted versus alternative monotherapies
(ADA, ETA, CTZ) showed that TCZ had a
greater likelihood of being the most effective
treatment in inducing ACR 20, 50, and 70
responses [34].
Hence, it must be pointed out that the
efficacy of TCZ, as mentioned in both
meta-analyses, must be interpreted with a
caution given the direct effect that the agent
has on CRP values, as the latter is a component
of the ACR and EULAR composite endpoints on
which the comparison was based. To confirm
the validity of the results of the meta-analyses,
it is important to remember that in some of the
most recent clinical studies investigating the
efficacy of TCZ monotherapy (ACT-RAY and
ADACTA studies) that the composite endpoints
were calculated using ESR values only. This
avoids potential bias due to CRP values, but at
the same time confirmed the greater efficacy of
TCZ [35, 36]. Hence, a post hoc analysis of the
ADACTA study [36], which used the Clinical
Disease Activity Index (CDAI) criterion (a
parameter that does not consider values such
as CRP or ESR to evaluate disease activity and
remission rates), also confirmed the efficacy of
TCZ, in agreement with the findings obtained
in the ADACTA study [35].
Given the limited effect on total costs, no
sensitivity analysis was conducted for
1370 Adv Ther (2016) 33:1360–1373
monitoring and administration of drugs. To
allow homogeneous comparison for the
biologic agents, the cost considered was the
NHS purchase cost net of compulsory legal
discounts only. Because it is difficult to
identify the actual drug cost that takes into
account all the discounts granted to hospital
structures, it was considered unreasonable to
conduct sensitivity analysis on this parameter.
As this economic analysis was conducted
from the Italian NHS perspective, the present
results may not be directly generalized to other
countries with different drug costs and
healthcare services reimbursement.
Furthermore, the analysis considered only the
economic impact of a few direct medical costs
(drugs, administration, and monitoring).
CONCLUSIONS
The results of the present economic assessment,
estimating the mean costs of NNT showed that
TCZ represents a cost-effective therapeutic
option in an NHS perspective compared to
other TNF-a inhibitors (ADA, ETA, CTZ) as
first-line monotherapy for patients who are
intolerant to MTX, or for whom it is
inappropriate to continue treatment with MTX.
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